The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy. Breast Cancer Index BCI , a molecular gene expression—based test used for determining which patients with early-stage, hormone receptor HR —positive breast cancer benefit from extended endocrine therapy, is now included in the National Comprehensive Cancer Network NCCN Guidelines for breast cancer, according to Biotheranostics, Inc. Per NCCN recommendations, BCI can be used for consideration of extended adjuvant endocrine therapy with a 2A category of evidence and consensus, which indicates uniform consensus from the organization that the recommendation is appropriate. The assay is the only of its kind to predict benefit of extended endocrine therapy in these patients and does so across 3 distinct groups. Appropriate therapy is grouped by patients benefiting from 5 years of tamoxifen followed by an additional 5 years of the same drug, those who should receive 5 years of tamoxifen followed by an additional 5 years of an aromatase inhibitor AI , and those who will benefit from 5 years with an AI followed by an additional 5 years of the same drug class.
Unexpected findings on weight loss and breast cancer from international study in JNCCN
Locoregional Management of Early-Stage Breast Cancer | NCCN Continuing Education
Jump to navigation. Locoregional management strategies have considerably evolved. Although several randomized studies have identified patients that do not need axillary lymph node dissection ALND , a recent survey revealed substantial variation in surgeon management suggesting the potential for overtreatment of many patients and the need for education in this area. Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximizes clinical benefit while minimizing toxicity. However many controversies exist as well. In order to define clinical situations that require radiation therapy and use the right approach, clinicians need to stay up-to-date on the updates and controversies. Benjamin O.
NCCN Issues First-Ever Guidance for Pediatric Solid Tumor
Advances in molecular testing have ushered in the new era of precision medicine. The publication of the TAILORx trial helped refine the use of genetic expression assays, specifically the gene recurrence score, in assigning patients to endocrine therapy alone or with chemotherapy. The algorithm for managing the axilla in early breast cancer has been further refined, based on the presence or absence of clinical evidence of lymph node involvement. Ovarian suppression has been validated as the optimal approach in higher risk premenopausal women, based on updated analysis of the SOFT and TEXT pivotal trials.
Jump to navigation. The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, it is difficult for clinicians to remain current on important criteria used in choosing optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.